GRAL trades 6.7% below Wall Street's consensus target of $73.43.
Last 12 months price action with 12-month analyst target path
The base valuation assumes GRAL achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, GRAIL, Inc. (GRAL) has a Wall Street consensus price target of $73.43, based on estimates from 6 covering analysts. With the stock currently trading at $68.79, this represents a potential upside of +6.7%. The company has a market capitalization of $2.82B.
Analyst price targets range from a low of $56.00 to a high of $130.00, representing a 101% spread in expectations. The median target of $60.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, GRAL trades at a trailing P/E of -6.2x. Analysts expect EPS to grow -6.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
EXASExact Sciences Corporation | $20.0B | $104.91 | $105.00 | +0.1% | Buy | 582.8x | 41 |
ILMNIllumina, Inc. | $29.1B | $191.76 | $156.27 | -18.5% | Buy | 36.6x | 50 |
GHGuardant Health, Inc. | $21.6B | $162.92 | $152.93 | -6.1% | Buy | — | 30 |
NTRANatera, Inc. | $40.3B | $281.27 | $261.00 | -7.2% | Buy | — | 27 |
FDMT4D Molecular Therapeutics, Inc. | $670M | $12.82 | $33.00 | +157.4% | Buy | — | 14 |
ACMRACM Research, Inc. | $6.3B | $94.66 | $110.00 | +16.2% | Buy | 47.4x | 10 |
CDNACareDx, Inc | $1.5B | $28.31 | $27.00 | -4.6% | Buy | 30.3x | 13 |
PACBPacific Biosciences of California, Inc. | $485M | $1.56 | $1.00 | -35.9% | Buy | — | 18 |
SEERSeer, Inc. | $122M | $2.22 | $4.00 | +80.2% | Hold | — | 4 |
TMOThermo Fisher Scientific Inc. | $192.0B | $516.62 | $592.45 | +14.7% | Buy | 20.8x | 42 |
Quick answers to the most common questions about buying GRAL stock.
The consensus price target for GRAL is $73.43, close to the current price of $68.79 (6.7% implied move). Based on 6 analyst estimates, the stock appears fairly valued near current levels.
GRAL has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $73.43 implies 6.7% upside from current levels.
GRAL's current price is $68.79 with a consensus target of $73.43 (6.7% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $130 for GRAL, while the most conservative target is $56. The consensus of $73.43 represents the median expectation. These targets typically reflect 12-month expectations.
GRAL is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month GRAL stock forecast based on 6 Wall Street analysts shows a consensus price target of $73.43, with estimates ranging from $56 (bear case) to $130 (bull case). The median consensus rating is "Buy".
GRAL appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $73.43 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
GRAL analyst price targets range from $56 to $130, a 101% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $73.43 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.